Drug Profile

AKY 2519

Alternative Names: ²²⁵Ac AKY 2519; Actinium-225-AKY 2519; AKY-2519

Latest Information Update: 13 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aktis Oncology
Class Antineoplastics; Drug conjugates; Proteins; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

31 Mar 2026 US FDA approves IND application for AKY 2519 in Solid tumours
31 Mar 2026 Aktis Oncology plans a phase I trial for Solid tumours in mid-2026
20 Jan 2026 AKY 2519 is available for licensing as of 20 Jan 2026. https://www.aktisoncology.com/join-us/?pag=1

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com